gasguide

Desflurane

Suprane

Fully fluorinated halogenated methyl ethyl ether — volatile general anesthetic

Same multi-site mechanism as sevoflurane: GABA-A + glycine potentiation, NMDA + nicotinic ACh inhibition, K⁺ channel activation.

Indications

  • GA maintenance (favored for fast emergence in obese / outpatient / long cases)
  • Not recommended for inhalational induction (pungency)

Dosing

ContextAdultPediatric
Maintenance (adult)3–8% inspired (1 MAC = 6.0% age 40; declines ~6%/decade)
Maintenance (pediatric)1 MAC age 1–5 y ≈ 8.6%; not used for mask induction (cough/breath-holding/laryngospasm)

Pharmacokinetics

Lowest blood:gas partition coefficient of clinical volatiles: 0.42 (vs sevo 0.65, iso 1.4). Translates to fastest emergence — particularly meaningful in obese patients and long cases. Negligible metabolism (~0.02%) → no fluoride or hepatotoxic intermediate concerns. Vapor pressure 681 mmHg at 20°C (almost atmospheric) requires HEATED, PRESSURIZED Tec 6 vaporizer.

Hemodynamic effects

Dose-dependent ↓SVR + ↓MAP (similar to sevo). UNIQUE: rapid increases in inspired concentration (>6%) cause sympathetic stimulation → HR + BP spike (mediated by airway irritation activating tracheo-bronchial receptors). Mitigate by gradual increase or pretreating with opioid/β-blocker.

Respiratory effects

PUNGENT — causes coughing, breath-holding, laryngospasm if increased rapidly. Contraindicated for inhalational induction. Otherwise similar respiratory profile to sevo (↓TV, ↑RR, bronchodilator, blunted CO₂ response).

Side effects

  • !Sympathetic stimulation with rapid inspired concentration changes (>6%) — ↑HR, ↑BP, can precipitate myocardial ischemia in CAD
  • !Carbon monoxide formation in DESICCATED CO₂ absorbents (especially old Baralyme; minimized with modern absorbents kept hydrated, FGF cycled off overnight)
  • !MH trigger
  • !Emergence cough/agitation if not weaned smoothly
  • !Highest greenhouse warming potential of clinical volatiles (~2540 GWP-100; ~25× sevo) — environmental consideration

Contraindications

  • ×MH susceptibility
  • ×Inhalational induction (pungency)
  • ×Severe coronary disease (relative — sympathetic surge risk with rapid concentration changes)

Clinical pearls

  • FASTEST emergence of any volatile — clinically meaningful for obese patients (where redistribution is slowed by adipose) and long surgeries.
  • Increase concentration GRADUALLY: 1% increments every few breaths to avoid sympathetic surge.
  • Tec 6 vaporizer is heated (39°C) and electrically controlled — different from variable-bypass vaporizers; needs power.
  • CO formation risk: turn off FGF overnight only with fresh hydrated absorbent OR keep absorbent moist; modern Amsorb eliminates risk.
  • Highest environmental impact volatile — many institutions favoring sevo for sustainability when fast emergence isn't critical.
Education only — confirm against current package inserts and institutional protocols. Doses assume normal organ function unless otherwise noted.